Italia Markets closed

Sanofi (0O59.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
97,19-0,16 (-0,16%)
Alla chiusura: 08:01AM BST
Schermo intero
Chiusura precedente97,35
Aperto97,19
DenaroN/D x N/D
DomandaN/D x N/D
Min-Max giorno97,85 - 98,46
Intervallo di 52 settimane77,04 - 105,14
Volume931
Media Volume1.010.056
CapitalizzazioneN/D
Beta (mensile su 5 anni)0,42
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utili25 lug 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis

    Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis Patients treated with amlitelimab experienced up to 61.5% improvement in average Eczema Area and Severity Index (EASI) score from baseline at week 16, the primary endpoint, with continued improvement seen through 24 weeksClinically meaningful improvements were seen in all key secondary endpoints at week 16 with continued improvements through week 24, including for IGA 0/1 where pat

  • GlobeNewswire

    Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

    Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment TEV’574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s diseaseCollaboration supports Sanofi’s immunology strategy of exploring novel mechanisms of action for chronic inflammatory diseasesCollaboration leverages the innovative R&D and commercial expertise of both companies Paris, France and Parsippany, New Jersey, October 4, 2023. Sanofi (EURONEXT: SAN and NASDA

  • GlobeNewswire

    Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli

    Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive ExPEC disease (IED) annually, worldwide1,2Phase 3 clinical trial of vaccine candidate ongoing. Novel ExPEC vaccine expected to complement existing older adult vaccine portfolio Paris, October 3, 2023. Sanofi announces today that it has entered into an agreeme